Page 22 - 2019_10 resto del Mondo_web

Editorials
References
1. Moschowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of terminal arterioles and capillaries: An undescribed dis- ease. Arch Intern Med.1925;36:89.
2. Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on throm- bopoiesis. I. A factor in normal human plasma required for platelet pro- duction; chronic thrombocytopenia due to its deficiency. Blood. 1960;16:943-957.
3. UpshawJDJr.Congenitaldeficiencyofafactorinnormalplasmathat reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med. 1978;298(24):1350-1352.
4. van Dorland HA, Mansouri Taleghani M, et al. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: Key findings at enrolment until 2017. Haematologica. 2019;104(10):2107- 2116.
5. KinoshitaS,YoshiokaA,ParkYD,etal.Upshaw-Schulmansyndrome revisited: a concept of congenital thrombotic thrombocytopenic purpu- ra. Int J Hematol. 2001;74(1):101-108.
6. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A. 2002;99(18):11902-11907.
7. LottaLA,GaragiolaI,PallaR,CairoA,PeyvandiF.ADAMTS13muta- tions and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010;31(1):11-19.
8. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494.
9. Scully M, Thomas M, Underwood M, et al. Thrombotic thrombocy- topenic purpura and pregnancy: presentation, management, and subse- quent pregnancy outcomes. Blood. 2014;124(2):211-219.
10. Camilleri RS, Cohen H, Mackie IJ, et al. Prevalence of the ADAMTS- 13 missense mutation R1060W in late onset adult thrombotic throm- bocytopenic purpura. J Thromb Haemost. 2008;6(2):331-338.
11. von Krogh AS, Quist-Paulsen P, Waage A, et al. High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. J Thromb Haemost. 2016;14(1):73-82.
12. AlwanF,VendraminC,LiesnerR,etal.Characterizationandtreatment of congenital thrombotic thrombocytopenic purpura. Blood. 2019;133(15):1644-1651.
13. Furlan M, Robles R, Morselli B, Sandoz P, Lammle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma thera- py in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999;81(1):8-13.
14. Taylor A, Vendramin C, Oosterholt S, Della Pasqua O, Scully M. Pharmacokinetics of plasma infusion in congenital thrombotic throm- bocytopenic purpura. J Thromb Haemost. 2019;17(1):88-98.
15. Scully M, Hibbard C, Ewenstein B. Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura. Oncoscience. 2017;4(11- 12):160-161.
1918
haematologica | 2019; 104(10)